| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
25,557 |
22,620 |
$1.10M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
9,487 |
8,732 |
$559K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
8,085 |
7,224 |
$387K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
11,133 |
5,245 |
$118K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
6,377 |
5,997 |
$68K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,809 |
2,556 |
$29K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
93 |
80 |
$11K |
| 71046 |
Radiologic examination, chest; 2 views |
366 |
334 |
$6K |
| 87807 |
|
592 |
549 |
$5K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
681 |
643 |
$4K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
187 |
170 |
$2K |
| 81003 |
|
1,543 |
1,463 |
$2K |
| 74018 |
|
113 |
110 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
27 |
27 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
597 |
543 |
$1K |
| 87428 |
|
24 |
23 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
551 |
512 |
$965.92 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
120 |
109 |
$359.38 |
| 73610 |
|
15 |
13 |
$316.10 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
718 |
673 |
$301.85 |
| 81025 |
|
14 |
14 |
$72.62 |
| 36415 |
Collection of venous blood by venipuncture |
12 |
12 |
$20.40 |